WASHINGTON — The U.S. Food and Drug Administration has approved the first new treatment for hepatitis C in 20 years.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The first-of-its-kind pill, called Victrelis, has been shown to cure more patients in less time than the older drugs now used. It's made by Merck.
About 3.2 million people in the U.S. have Hepatitis C, which is linked to 12,000 deaths a year.
The current two-drug treatment for the virus cures only about 40 percent of people and causes side effects like nausea, fatigue and vomiting.
Merck's drug has been shown to boost cure rates to between 60 and 65 percent when added to the older drugs.
It works by blocking an enzyme that helps hepatitis reproduce. It differs from the older medications that boost the immune system.
Copyright 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.